This letter reports on the first-year experience of using treprostinil DPI in pulmonary hypertension associated with ILD, suggesting its potential benefit.
A dry powder inhaler (DPI) formulation of treprostinil was FDA‐approved in March 2022 for patients with pulmonary arterial hypertension or pulmonary hypertension associated with ILD (PH‐ILD). In this letter we describe our real‐world single‐center experience using Treprostinil DPI in patients with PH‐ILD patients within our first year of using this medication.
No takes yet. Share an insight, caveat, or question.
Rice et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: